We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Inherited Gene Mutation Leads to Ovarian Cancer

By LabMedica International staff writers
Posted on 03 Feb 2016
Print article
Image: Histopathology of epithelial ovarian cancer (Photo courtesy of the Human Protein Atlas).
Image: Histopathology of epithelial ovarian cancer (Photo courtesy of the Human Protein Atlas).
Women who carry an inherited fault in a certain gene are more than three times more likely to develop epithelial ovarian cancer (EOC) than those without the mutation.

Risk prediction based on identifying germline mutations in ovarian cancer susceptibility genes could have a clinically significant impact on reducing disease mortality as around 18 women in every 1,000 develop ovarian cancer, but this risk increases to around 58 women in every 1,000 for women with a mutation in a specific gene.

An international team of scientists led by those at the University of Cambridge Cancer Group (UK) compared the genes of more than 8,000 white European women which included around 3,250 women diagnosed with ovarian cancer, 3,400 women who did not have cancer and 2,000 women who had a family history of the disease. For each gene, they estimated the prevalence and EOC risks and evaluated associations between germline variant status and clinical and epidemiological risk factor information.

Next generation sequencing was used to identify germline mutations in the coding regions of four candidate susceptibility genes: BRCA1 Interacting Protein C-Terminal Helicase 1 (BRIP1), BRCA1 Associated RING Domain 1 (BARD1), Partner and Localizer of BRCA2 (PALB2) and Nibrin (NBN). The scientists found an increased frequency of deleterious mutations in BRIP1 in case patients (0.9%) and in the participants from a clinical screening trial of ovarian cancer (UKFOCSS) (0.6%) compared with control patients (0.09%), but no differences for BARD1, NBN1 or PALB2.

The authors concluded that deleterious germline mutations in BRIP1 are associated with a moderate increase in EOC risk. These data have clinical implications for risk prediction and prevention approaches for ovarian cancer and emphasize the critical need for risk estimates based on very large sample sizes before genes of moderate penetrance have clinical utility in cancer prevention.

Paul D. P. Pharoah, MD, a professor of Cancer Epidemiology and co-director of the study, said, “Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatest risk. Finding these women will help us prevent more cancers and save lives. This would be important in a disease like ovarian cancer, which tends to be diagnosed at a late stage when the chances of survival are worse.” The study was published in the January 2016 edition of the Journal of the National Cancer Institute.

Related Links:

University of Cambridge Cancer Group


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.